Barrington Research Reiterates Conceptus Outperform, $20 PT

Barrington Research reiterated its Conceptus (NASDAQ: CPTS) Outperform rating and $20 price target in a research report published today.

In the report, Barrington Research states, "There is no doubt that CPTS has some incredible opportunities ahead of it within Medicaid and with the expected AAGL position paper which we believe will significantly accelerate growth in 2012. We believe Essure is the best device with the most cost effective, efficacious and safe solution on or near to market with improving fourth and fifth generation devices in the pipeline."

Shares of Conceptus closed today at $12.83, up 0.94% from Monday's market close.